Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471736 | 1.00 | SLC6A2 (0.63) | SLC6A2DPP3OPRM1OPRD1CAPN1 | |
| SCHEMBL30392261 | 0.90 | DPP3 (0.61) | SLC6A2DPP3OPRM1CAPN1CTSB | |
| SCHEMBL29772686 | 0.90 | DPP3 (0.65) | SLC6A2DPP3OPRM1 | |
| SCHEMBL29577213 | 0.90 | DPP3 (0.65) | SLC6A2DPP3OPRM1 | |
| SCHEMBL30659496 | 0.90 | DPP3 (0.64) | DPP3OPRM1OPRD1 | |
| SCHEMBL29683171 | 0.90 | KISS1R (0.62) | SLC6A2OPRM1CAPN1CTSB | |
| Spinorphin SCHEMBL25273730 | 0.89 | KISS1R (0.60) | SLC6A2DPP3OPRM1CAPN1CTSB | |
| Spinorphin SCHEMBL25217672 | 0.89 | KISS1R (0.60) | SLC6A2DPP3OPRM1CAPN1CTSB | |
| SCHEMBL29363938 | 0.88 | SLC6A2 (0.78) | SLC6A2OPRM1OPRD1 | |
| Endomorphin-1 SCHEMBL21811384 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410307-B | Neutralizing antibody for neutralizing SARS-CoV-2 in six strains and its application | TSINGHUA UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250346657-A1 | CANINIZED AND FELINIZED ANTIBODIES TO HUMAN NGF | INTERVET INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4608449-A1 | ANTI-C5 ANTIBODY/C5 IRNA CO-FORMULATIONS AND COMBINATION THERAPIES | Regeneron Pharmaceuticals, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| CN-113908268-B | Use of antibodies in the preparation of a medicament for the treatment or prevention of migraine | 美国安进公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-116103173-B | Method for improving malonic acid production by saccharomyces cerevisiae | 江南大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-113993898-B | RET-binding human antibodies and methods of use thereof | 瑞泽恩制药公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-113874078-B | Anti-TAUC 3 antibody and application thereof | TAUC3生物制品有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-113795514-B | Method for producing antibodies | 豪夫迈·罗氏有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-113767115-B | Therapeutic interferon alpha 1 proteins | 奥里尼斯生物科学股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-107253992-B | Monoclonal antibody against HER2 | 根马布股份公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114144435-A | Antibodies against human TREM-1 and uses thereof | 百时美施贵宝公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-113527496-B | anti-Trop 2 nano antibody and application thereof | 上海洛启生物医药技术有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-114106174-A | Low toxicity anti-OX 40 antibodies, pharmaceutical compositions and uses thereof | 苏州景涞医疗科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114127305-A | Ligand discovery and gene delivery via retroviral surface display | 麻省理工学院 | 2022-03-01 | — | — | CN | disclosed |
| CN-108026170-B | anti-CD 71 antibodies, activatable anti-CD 71 antibodies, and methods of use thereof | 西托姆克斯治疗公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-114127125-A | Multispecific thyroxin transporter immunoglobulin fusions | 安进公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-107840893-B | Novel anti-PCSK 9 antibodies | 信立泰(成都)生物技术有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-114057881-A | Anti-ketamine specific antibody, plasmid vector and method | 杭州贤至生物科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | LDLR, CHRNG, FCGR2A | SLC6A2 2979/4885DPP3 1986/4885OPRM1 1870/4885 |
| US-20250346657-A1 | CANINIZED AND FELINIZED ANTIBODIES TO HUMAN NGF | NGF, NTRK1, BDNF | SLC6A2 361/4885DPP3 2983/4885OPRM1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.